Fenwick Represents Graybug Vision in $80M Series C Financing

Fenwick & West represented Graybug Vision, a clinical-stage pharmaceutical company developing therapies for ocular diseases, in its $80M Series C financing led by CBC Group (formerly C-Bridge Capital), with participation from existing investors Deerfield Management, OrbiMed Advisors, Hatteras Venture Partners, a fund managed by Blackstone Life Sciences and other new investors.

Graybug Vision will use the funding to advance its retina and glaucoma clinical programs. More information can be found in the company announcement.

The Fenwick transaction team was led by corporate partners Effie Toshav and Michael Brown and associates Julia Forbess and Elliot Ginsburg.